⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

BRIEF-Aptose Biosciences provides update on APTO-253 development

Published 2016-12-29, 08:38 a/m
© Reuters.  BRIEF-Aptose Biosciences provides update on APTO-253 development
APS
-

Dec 29 (Reuters) - Aptose Biosciences Inc APS.TO :

* Aptose Biosciences provides update on apto-253 development

* Aptose Biosciences Inc - has successfully manufactured multiple batches of a new drug product formulation for APTO-253

* Aptose Biosciences - will have to repeat production of fourth batch, a 40l batch that was intended clinical supply

* Aptose Biosciences - will have to repeat production of fourth batch because of a correctable engineering design incompatibility during filling process

* Aptose - "while we have encountered delays in manufacturing activities, we also have continued mechanistic and pharmacokinetic testing of APTO-253"

* Aptose Biosciences Inc - also continue to advance development of CG'806

* Aptose -expects batch records,release specifications from such new batch, alongwith stability,sterility data,be provided to FDA during q1 2017

* Aptose Biosciences provides update on apto-253 development Source text for Eikon: ID:nGNXNNRNQa Further company coverage: APS.TO

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.